Menopause, Hormone Treatment and Urinary Incontinence at Midlife

Authors

Guillaume Legendre 1,2
Virginie Ringa 1
Arnaud Fauconnier 3,4
Xavier Fritel 5,6

Institutions

1. INSERM UMRS 1018, CESP Centre for Research in Epidemiology and Population Health, U1018, Gender, Sexual and Reproductive Health Team, Paris-Sud University, Villejuif, and Institut National des Etudes Démographiques, Paris, France

2. Bicêtre University Hospital, Assistance Publique-Hôpitaux de Paris, Le Kremlin Bicêtre, France.

3. Research unit EA 7285, Versailles-St-Quentin University, Montigny-le-Bretonneux, France.

4. Poissy-Saint-Germain-en-Laye Hospital, Poissy, France

5. INSERM CIC0802, Poitiers University Hospital, Poitiers University, France.

6. INSERM UMR S953, Epidemiological Research on Perinatal Health and Women and Children Health, Paris 6 University, Paris, France

Correspondence

Prof Xavier Fritel
Service de Gynécologie-Obstétrique et Médecine de la Reproduction,
CHU de Poitiers, 2 rue de la Milétrie, F-86000 Poitiers, France.
Phone: +33 549 443 360; fax: +33 549 443 910
xavier.fritel@univ-poitiers.fr
Abstract

Whether there is any association between urinary incontinence and menopause is the subject of debate, partly due to the fact it is difficult to tell the difference between the effects of menopause and those of ageing. For some time it was hoped that hormonal treatment for menopause would be beneficial for urinary incontinence because there are hormonal receptors in the urinary tract. The goal of this survey of current knowledge on the subject is to explore thoroughly the relationship between menopause and urinary incontinence.

Our study is based on a review of the literature dealing with the epidemiology of urinary incontinence in women aged between 45 and 60, and the effects of hormonal treatment with respect to the symptoms of involuntary loss of urine.

Analysis of the epidemiological data drawn from large cohorts shows that on the one hand, the menopause has little if any impact on the risk of urinary incontinence, and on the other hand that the effects of oestrogen medication on urinary incontinence vary according to how it is administered and the type of incontinence. The effect of oral hormone treatments for menopause is rather negative with respect to stress incontinence. Vaginal treatment appears to be beneficial for overactive bladder symptoms.

Key-words: Urinary Incontinence, Stress Urinary Incontinence, Urge Incontinence, Overactive bladder, Menopause, Hormone therapy, Oestrogen, Epidemiology.

No conflicts of interest to declare.
1. Introduction

The menopause is a universal physiological event related with the drop in ovarian hormone secretions (œstrogens and progestin) that occurs as the stock of ovarian follicules is depleted. Menopause is diagnosed when menstruation has stopped for 12 successive months, and the average age at which it occurs is between 47 and 51 [1,2]. Its clinical expression varies very considerably between socio-cultural groups and individuals [3]. These variations depend on many factors, such as women's social status, their nutrition, life style (smoking) and weight, not forgetting genetic factors [3]. It is difficult to draw the distinction between the effects of menopause and those of ageing. In addition to the menopausal "syndrome" itself, which mainly comprises vasomotor symptoms and vaginal dryness, urinary symptoms including incontinence (UI) have been attributed to menopause. The hormonal dependence of the genital tract tissues has been evoked in order to explain the appearance of these female low urinary tract symptoms (FLUTS) at the menopause. Estrogen receptors have been found not only in the pelvic floor muscles but also in the uro-genital ligaments and detrusor muscle cells along with the connective tissues and all the fascias that maintain a stable relationship between the various organs [2].

Urinary incontinence can be defined as "the complaint of any involuntary leakage of urine" [4]. The standard classification gives three main types of UI: Stress Urinary Incontinence (SUI), Urge Urinary Incontinence (UUI) and Mixed Urinary Incontinence (MUI). Stress urinary incontinence is characterised by involuntary loss of urine without any previous feeling of a need to void, which takes place on the occasion of a physical stress (cough, lifting something heavy, or any other physical activity). Urge urinary incontinence (or urgent need to void) is characterised by involuntary loss of urine preceded by an urgent and irresistible need to void resulting in uncontrollable leakage of urine. Mixed urinary incontinence is the association in variable proportions of SUI and UUI.

UI may be experienced simply as a nuisance or as a real handicap [5,6]. Women frequently present the symptoms of UI, but the estimates for its prevalence in the general population vary widely, from 8 to 30 %. This variability is due not only to the very heterogeneous nature of the populations studied but also to the varying definitions of UI used in the studies.

Many different factors are associated with an increased risk of UI [7]. The main of these are ageing, pregnancy, childbirth, past history of pelvic and perineal surgery, obesity, and chronic pathologies (diabetes, cognitive problems, etc.). There is more debate about the roles of menopause and hormone replacement therapy (HRT) [8,9]. As mentioned above, it is difficult
to differentiate between the role of ageing and that of the menopause, and equally to
differentiate the true role of menopause from that of treatments instigated at the time of
menopause, such as HRT.

The relationship postulated between UI and hormone deficiencies induced by menopause is
based mainly on "physiological" data, i.e. the existence of (œstrogen and progestin) hormonal
receptors in the epithelial tissues of bladder, urethra and trigone and also in the vagina,
uterosacral ligaments, levator ani and puborectal muscles [10]. The other argument supporting
this relation is clinical observation of an increase in the prevalence of overactive bladder
(OAB) syndrome after the menopause. The lack of œstrogens could contribute in various
ways to other urinary symptoms that arise: œstrogens play a role in (i) the increase in
epithelial cellular trophicity in the vagina, urethra and bladder (ii) the increase in peri-urethral
vascularisation (an important factor for regulation of closing pressure), (iii) the increase in
maximum closing pressure and (iv) the increase in concentration and sensitivity of \( \alpha \)-
adrenergic receptors with modification of the \( \alpha \)-adrenergic receptors/\( \beta \)-adrenergic receptor
ratio in favour of the \( \alpha \)-adrenergic receptors [11-13]. Progestin receptors are also to be found
in the entire female genital tract, although in less constant fashion than œstrogen receptors.
Progestin appears to have a detrimental effect on continence, by reducing muscle tone of
bladder and urethra [10].

The aim of our review is to analyse the data in the literature with respect to the relationship
between menopause and UI. We present the main epidemiological data dealing with the
relationship between prevalence, incidence and remission of UI, and the menopause. We then
try to supply answers to the two main questions raised by this relationship: What
consequences do hormonal changes at the menopause have on UI symptoms? What
consequences do hormonal treatments have on continence?

2. Methods:

A review of the literature was carried out by consulting the Medline database entries between
January 2000 and June 2012. Articles were selected by cross-referencing the following
keywords: "urinary incontinence, stress urinary incontinence, urge incontinence, overactive
bladder, menopause, œstrogen therapy". In this selection priority was given to meta-analyses,
literature reviews, randomised controlled trials and cohort studies. The level of evidence (LE)
scale proposed by the Oxford Centre for Evidence-Based Medicine (www.cebm.net) was used to class the articles selected. The terminology used complies with International Continence Society (ICS) and International UroGynecological Association (IUGA) recommendations.

3. Results

3.1. Study selection

Among the 488 articles initially selected during the Medline search, 29 articles were finally retained, including 3 meta-analyses, 4 literature reviews, 5 randomised controlled trials and 12 cohort studies. Figure 1 gives details on this selection of articles.

3.2. Prevalence or incidence of UI according to age

The prevalence of urinary incontinence is proportional to age. The distribution of the various types of UI changes with age. Several articles report a peak in the prevalence of SUI at midlife (LE3). The majority of cases before the age of 50 are SUI, but after that age it represents a minority [14]. After 60 it is mixed UI that predominates. The prevalence of UI at the time of menopause varies from 8 to 27% depending on the population studied and the definition used for UI [14-17] (LE2).

Only a few cohort studies specifically address the menopause period (45-60 years). Mac Grother et al. report an annual incidence of UI of 8% in a population of 108 women aged between 40 and 59 in the general population [16] (LE3). Two other cohorts of women under the age of 60 found annual incidence rates at 4 and 5% [15, 17] (LE3). In another cohort of 2860 femmes between 40 and 60, the authors report an annual incidence rate of 6% [18] (LE3). A longitudinal study of a cohort of nurses aged 36 to 55 by Townsend et al. found an annual incidence of 7% [19] (LE3).

There is considerable disparity between the cohort studies concerning the annual rate of remission. On the one hand Hagglund [17], Samuelsson [20], and Townsend [19] report annual remission rates for UI of 4, 6, and 7% respectively (LE3). On another hand other authors report higher annual remission rates, at 25 to 29% [16, 18] (LE3). These results can be explained in part by the definition of remission of UI depending on the studies: complete disappearance or lessening of the severity of UI symptoms.
3.3. Prevalence or incidence of UI according to menopausal status

The American prospective cohort *Study of Women’s Health Across the Nation (SWAN)* followed 1529 women, without any UI symptoms at inclusion, annually for 6 years. The women were classed according to their hormonal status at the end of the study as follows: pre-menopause, early peri-menopause (irregular menses), late peri-menopause (3 to 11 months amenorrhoea), and post-menopause (over 12 months amenorrhoea). The peri-menopause period is associated with an increased risk of UI for all types of UI together (OR= 1.52 [95% CI: 1.12–2.05] in late peri-menopause) but this association disappears post-menopause (0.88 [0.63-1.23]). Analysis by the type of UI shows that this association with the peri-menopause above all concerns UUI (2.12 [1.26-3.56] in late peri-menopause) while the association is non significant for SUI (1.24 [0.75-2.05] in late peri-menopause). Analysis of frequent UI alone (at least one episode of UI a week) does not show any association with early peri-menopause (0.99 [0.60-1.63]), late peri-menopause (1.14 [0.51-2.54]), or post-menopause (1.10 [0.46-2.64]) (LE2) [21]. In another study covering 2415 women from the SWAN cohort who were incontinent (at least one episode of UI per month) at inclusion, Waetjen reports that the worsening of UI symptoms observed after the menopause is not attributable to the menopause itself [22] but to an increase in weight. The menopause appears to be associated with an increase in weight and this would explain the increase in the prevalence of UI (LE2).

The study by Sherburn *et al.* of the Australian cohort of 1897 femmes, *The Melbourne Women’s Midlife Health Project*, addressed the impact of the menopause on UI symptoms. Simultaneous cross-sectional and longitudinal analysis of the data did not reveal any statistical relationship between UI and menopause (LE3). In the longitudinal analysis of 438 women from the same cohort who were followed for 7 years the menopause was not associated with any increase in the incidence of UI as a whole (LE3) [15].

The results obtained by another longitudinal study, the *National Survey of Health and Development (NSHD)* concerning 1211 women between 48 and 54 years of age did not find any association between menopause and UUI (LE3). SUI alone was associated with the hormonal status, since in this study the peri-menopause was associated with an increased prevalence of urine leakage symptoms due to stress, as compared with the group of post-menopausal women (OR= 1, 39 [1, 4-1, 7]) (LE3). This study, in which it is not possible to distinguish clearly between the effects of age and those of menopause because there is no comparison of the incidence rates between the different groups, nevertheless appears to reveal
an effect of ageing independent of that of the menopause with respect to the occurrence of UUI or SUI (LE3) [23].

A large Chinese cross-sectional study of nearly 20,000 women aged 20 to 99 shows an association between SUI and menopause (OR = 1.26 [1.04-1.52]), even when age is taken into account as a risk factor (LE4) [24].

3.4. Prevalence or incidence of UI according to hormone levels

A recent cohort study looked at the effect of changes in oestrogen concentrations on urinary symptoms during the transition to menopause. A big drop in oestrogen levels is associated in significant fashion with an improvement in UI symptoms (LE2) [25]. Moreover, analysis of the annual fluctuation in endogenous oestrogen levels during the menopausal period using the data from SWAN did not find any association with the onset of UI or worsening of UI symptoms (LE2) [26]. A Swedish cohort study of 6,917 women aged between 50 and 59 even found a positive association between a high oestradiol level and UI (LE2) [27].

3.5. Prevalence or incidence of UI depending on menopause hormonal treatment

3.5.1. Data obtained from random studies of women treated for urinary symptoms

A meta-analysis based on eleven randomised studies of the effects of oestrogen (versus placebo) on overactive bladder symptoms found a significant association between oestrogen treatments and an improvement in the urinary symptoms: less pollakiuria and nocturia, fewer episodes of UUI and urine leaks, improvement in the latency of the first urge to void and increase in bladder capacity (LE1) [28]. However, the effects vary according to the mode of administration of the oestrogens. Local application (vaginal or intravesical) is associated in significant fashion with an improvement in all the urinary symptoms (pollakiuria, nocturia, UUI, bladder capacity). Systemic administration results in only partial improvement of these symptoms, and statistically is associated only with a drop in the number of episodes of incontinence and later perception of the first urge to void.

A review of the literature covering several randomised trials (comparisons between different protocols for oestrogen treatment or versus placebo) confirms the advantage of vaginal treatments in case of post-menopausal lower urinary tract symptoms, especially in the presence of vaginal atrophy (LE2) [11]. The findings of recent studies of the effect of
œstrogens in association with anti-muscarini agents did not agree. A controlled study of 229 femmes presenting an overactive detrusor did not show any benefit for topical vaginal œstrogen therapy associated with tolterodine versus tolterodine alone for overactive bladder symptoms (LE2) [29]. Another randomised controlled trial in 80 women with overactive bladder syndrome, also comparing the effect of topical vaginal œstrogen therapy associated with tolterodine with that of tolterodine alone, found a significant improvement of objective parameters and quality of life when œstrogens were associated with tolterodine (LE2) [30]. Finally, a recent randomised trial comparing the efficiency of topical vaginal œstrogen therapy with that of oxybutynin for the treatment of overactive bladder syndrome found that the two products were similar in terms of efficiency (LE2) [31].

A review of the literature covering eight controlled studies and 14 prospective non-controlled studies concluded that œstrogen treatment is not efficient for SUI (LE2) [32].

3.5.2. Data resulting from secondary analyses of randomised trials in the general population

Among the post-menopausal women enrolled in the Womens’ Health Initiative study (WHI), HRT significantly increased the incident risk at one year of all types of UI (SUI, UUI, MUI) in women who were continent at the time they were included (LE2). This effect of HRT is particularly distinct for SUI and less so if at all for UUI [33]. In women taking oral œstrogens and progestin, the relative risk of de novo UI is 1.87 [1.61-2.18] for SUI, 1.15 [0.99-1.34] for UUI and 1.49 [1.10-2.01] for MUI. The results are similar for women taking œstrogen alone: 2.15 [1.77-2.62], 1.32 [1.10-1.58], and 1.79 [1.26-2.53] respectively. In women who were incontinent when included, HRT slightly increased the quantity lost (1.20 [1.06-1.36] when treated using œstrogen and progestin and 1.59 [1.9-1.82] when treated with œstrogen alone), and the frequency of leaks (1.36 [1.28-1.49] and 1.47 [1.35-1.61] respectively) [33].

Steineauer et al. carried out a subsidiary analysis of the Heart Estrogen/Progestin Replacement Study (a double-blind randomised study assessing the effect of HRT for prevention of cardiovascular risks) concerning patients with no UI at inclusion [34]. A significant relationship between HRT and the onset of both UUI and SUI was found during the first four months of treatment. This detrimental effect of HRT persisted throughout the 4 years of the study, with a cumulated additional risk of 12% and 16 % respectively for UUI and SUI compared with treatment by placebo (LE2).
The results of these studies were included and confirmed in the Cochrane Database [35] meta-analysis which covered a total of 19,313 incontinent women among whom 9,417 were treated by oestrogens, in 33 studies (16 of which addressed specifically SUI). There was no analysis by type of UI. A worsening of UI symptoms was found when HRT was taken systemically (RR = 1.32 [1.17-1.42]) (LE1). However, topical vaginal oestrogen therapy contributed towards remission of UI by improving both the episodes of urge urinary incontinence (0.74 [0.64-0.86]) and pollakiuria (LE1).

3.5.3. Data obtained from cohort studies

The data of the Nurses’ Health Study addressing the impact of HRT on UI in a cohort of nurses aged between 30 and 55 at the time of inclusion were analysed by Grodstein et al. [36]. The occurrence of incident UI was associated in significant fashion with systemic hormone therapy whatever the type of HRT and mode of administration: oral oestrogen (RR = 1.54 [1.44-1.65]), transdermal oestrogen (1.68 [1.41-2.00]), oral oestrogen and progestin (1.34 [1.24-1.44]) and transdermal oestrogen and progestin therapies (1.46 [1.16-1.84]) (LE3). The overall risk of UI remained low however, with an annual incidence of 1.6%, and the effects of HRT disappeared when treatment ceased.

A recent cohort study of post-menopausal women found an association between UI symptoms and duration of oestrogen treatment. Prolonged oral oestrogen therapy (5 years or more) is associated with a worsening of leakage symptoms (OR = 3.99 [1.21-13.1]) and also an increase in the frequency of handicapping UI (3.97 [1.02-15.4]) [37] (LE3).

3.5.4. Data obtained from studies concerning intermediate markers

Certain older studies report that the use of oral oestrogens appears to increase the urethral closing pressure and could thus improve SUI symptoms in 65 to 70% of women [38] (LE5). Two randomised controlled trials concerning the oral route versus placebo to treat UI and including 83 and 67 post-menopausal women were unable to demonstrate any effect of oestrogens with respect to urodynamic parameters or urinary symptoms, whether in terms of objective measurements (pad-test, cystometry, prolifometry) or in terms of subjective measurements (assessed by approved quality of life questionnaires) [39] (LE2).
3.5.5. Influence of hormonal treatment after surgery for SUI

Certain studies looked at the impact of oestrogen therapy when surgery is used for SUI. A prospective randomised study comparing the effects of adjuvant topical vaginal oestradiol or not for six months immediately after surgical correction of SUI using a sub-urethral tape (TVT-O) in 183 post-menopausal patient, found that pollakiuria (2 vs. 11 %, p=0.02) and urge urinary incontinence (3 vs. 12 %, p= 0.01) alone were improved by hormone therapy (LE2) [40]. The objective parameters of the urodynamic tests remained unchanged in both groups (LE2). In a randomised controlled trial Zullo et al. found exactly the same results with urge urinary incontinence alone being improved by topical vaginal oestrogen therapy (LE2) [41]. No study of the long-term advantages of oestrogen after installation of a sub-urethral tape was found.

4. Discussion

The results of our review concerning the link between menopause and UI do not all agree, but this overview shows that the menopause has little if any impact on the risk of UI in general, when confounding factors such as age or changes in weight are taken into account. It appears that SUI decreases after the menopause while UUI or mixed UI increase at this time. Oral HRT has a rather detrimental effect on stress urinary incontinence, by doubling the risk of de novo SUI. Concerning UUI, HRT has less of an effect, which is variable according to the population in question and the type of treatment. Topical vaginal oestrogen therapy is the only treatment that seems to have a really beneficial effect on urge urinary incontinence or overactive bladder symptoms.

Most of these results are drawn from longitudinal analyses of large cohorts enabling a distinction to be drawn between the effect of age and that of the menopause. Longitudinal studies are the only way to examine the timing, and consequently any cause and effect relationship between events. Cross-sectional studies cannot assess time-dependent variables such as age, weight and menopausal status. Nevertheless, the large cohort studies included in this review present several problems. For example, the definition of UI is not identical in all the studies because follow-up of the cohorts often started prior to the harmonisation of the terminologies proposed by ICS and IUGA. The frequency of UI as a "functional complaint" depends on the tools used. Moreover, few of the studies draw a distinction between the various types of UI (SUI, UUI, MUI), their frequency or their severity. Finally in this type of
cohort, the lack of any overall assessment of incontinence risk factors (because the studies were not designed initially to study this problem specifically) can result in confounding biases.

Part of the results of this review is based on secondary analyses of randomised trials in which the main objective was not to study UI but instead the cardiovascular morbidity of HRT. So the level of evidence contributed by these secondary analyses is lower.

Certain pathophysiological data would tend to indicate a worsening of UI due to lack of œstrogen. However, in contradiction with this postulate, the epidemiological data obtained with the cohorts shows that the menopause has little if any effect on urinary symptoms. The results of several large randomised trials in the general population reveal an aggravation of UI in case of systemic HRT. This detrimental effect of HRT needs to be seen in the light of what is observed during pregnancy, when an increase in the prevalence of UI is observed [42]. This greater prevalence of UI during pregnancy could be explained by the increase in œstrogen concentrations.

Topical vaginal œstrogen therapy alone appears to have a beneficial effect on overactive bladder symptoms. This effect could be explained by the improvement in terms of vaginal dryness and a drop in recurrent urinary infections [8,11]. The learned societies do not recommend the use of œstrogens (whether or not associated with progesterone) for the treatment of UI. However, in case of overactive bladder symptoms in a post-menopausal woman, topical vaginal treatment may be proposed [43,44].

5. Conclusion

Female urinary incontinence is a complex and dynamic phenomenon, related with age and a many other factors that can change with time. In order to gain greater insight, longitudinal studies are necessary, with several years or even decades of follow-up in order to clarify its evolution and risk factors.

The onset and/or worsening of UI at the menopause that is expected on the basis of physiological observations is not confirmed by the results of most of the epidemiological studies that mostly cover a large number of women followed up over many years. Moreover, correction of the lack of œstrogen by HRT gives rise to paradoxical results that depend on the type of UI and mode of administration. Systemic œstrogen therapy results in an increase in UI
symptoms and SUI in particular. Topical vaginal administration appears to be the most beneficial by improving overactive bladder symptoms.

6. References


